These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32609446)

  • 1. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
    Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
    Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
    Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
    Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
    [No Abstract]   [Full Text] [Related]  

  • 4. IgA Vasculitis Developed as an Adverse Effect of Tofacitinib Taken for Rheumatoid Arthritis.
    Itoh I; Kasuno K; Yamamoto C; Takahashi N; Shimizu H; Ojima T; Hayashi S; Kimura H; Iwano M
    Intern Med; 2020 Mar; 59(6):817-821. PubMed ID: 31813912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
    Noell C; Arbeit R; Kanhoush R
    Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A; Mahmood F; Wittmann M; Helliwell P
    Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
    Di Lernia V; Bardazzi F
    Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tofacitinib].
    Döker S; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Kuo CM; Tung TH; Wang SH; Chi CC
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
    Clowse ME; Feldman SR; Isaacs JD; Kimball AB; Strand V; Warren RB; Xibillé D; Chen Y; Frazier D; Geier J; Proulx J; Marren A
    Drug Saf; 2016 Aug; 39(8):755-62. PubMed ID: 27282428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase inhibitors in dermatology: A systematic review.
    Shreberk-Hassidim R; Ramot Y; Zlotogorski A
    J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D; O'Dell KM; Bandy JL; Boyce EG
    Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 16. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
    Sonomoto K; Tanaka Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK inhibitors in dermatology: The promise of a new drug class.
    Damsky W; King BA
    J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review.
    Utama A; Wijesinghe R; Thng S
    Int J Dermatol; 2024 Aug; 63(8):1020-1035. PubMed ID: 38610078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.